302 related articles for article (PubMed ID: 23024219)
1. Responsiveness of FGF-23 and mineral metabolism to altered dietary phosphate intake in chronic kidney disease (CKD): results of a randomized trial.
Sigrist M; Tang M; Beaulieu M; Espino-Hernandez G; Er L; Djurdjev O; Levin A
Nephrol Dial Transplant; 2013 Jan; 28(1):161-9. PubMed ID: 23024219
[TBL] [Abstract][Full Text] [Related]
2. Diabetes modifies effect of high-phosphate diet on fibroblast growth factor-23 in chronic kidney disease.
Muras K; Masajtis-Zagajewska A; Nowicki M
J Clin Endocrinol Metab; 2013 Dec; 98(12):E1901-8. PubMed ID: 24092829
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal Evolution of Markers of Mineral Metabolism in Patients With CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study.
Isakova T; Cai X; Lee J; Mehta R; Zhang X; Yang W; Nessel L; Anderson AH; Lo J; Porter A; Nunes JW; Negrea L; Hamm L; Horwitz E; Chen J; Scialla JJ; de Boer IH; Leonard MB; Feldman HI; Wolf M;
Am J Kidney Dis; 2020 Feb; 75(2):235-244. PubMed ID: 31668375
[TBL] [Abstract][Full Text] [Related]
4. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women.
Burnett SM; Gunawardene SC; Bringhurst FR; Jüppner H; Lee H; Finkelstein JS
J Bone Miner Res; 2006 Aug; 21(8):1187-96. PubMed ID: 16869716
[TBL] [Abstract][Full Text] [Related]
5. A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5.
Block GA; Fishbane S; Rodriguez M; Smits G; Shemesh S; Pergola PE; Wolf M; Chertow GM
Am J Kidney Dis; 2015 May; 65(5):728-36. PubMed ID: 25468387
[TBL] [Abstract][Full Text] [Related]
6. Dietary and pharmacological modification of fibroblast growth factor-23 in chronic kidney disease.
Adema AY; de Borst MH; Ter Wee PM; Vervloet MG;
J Ren Nutr; 2014 May; 24(3):143-50. PubMed ID: 24216259
[TBL] [Abstract][Full Text] [Related]
7. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers.
Larsson T; Nisbeth U; Ljunggren O; Jüppner H; Jonsson KB
Kidney Int; 2003 Dec; 64(6):2272-9. PubMed ID: 14633152
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast growth factor 23 (FGF 23) and phosphocalcic metabolism in chronic kidney disease.
Torguet-Escuder P; Guasch-Aragay B; Calabia-Martínez J; Martín-Alemany N; García-Méndez I; Maté-Benito G; Clapés-Sánchez E; Sabater-Masdeu M; Fernández-Real JM; Vallès-Prats M
Nefrologia; 2012; 32(5):647-54. PubMed ID: 23013951
[TBL] [Abstract][Full Text] [Related]
9. Relationship between Fibroblast Growth Factor 23 and Biochemical and Bone Histomorphometric Alterations in a Chronic Kidney Disease Rat Model Undergoing Parathyroidectomy.
Liao HW; Hung PH; Hsiao CY; Liou HH; Lin HS; Huang TH; Jou IM; Tsai KJ
PLoS One; 2015; 10(7):e0133278. PubMed ID: 26186634
[TBL] [Abstract][Full Text] [Related]
10. Effect of a non-calcium-based phosphate binder on fibroblast growth factor 23 in chronic kidney disease.
Spatz C; Roe K; Lehman E; Verma N
Nephron Clin Pract; 2013; 123(1-2):61-6. PubMed ID: 23774446
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men.
Ferrari SL; Bonjour JP; Rizzoli R
J Clin Endocrinol Metab; 2005 Mar; 90(3):1519-24. PubMed ID: 15613425
[TBL] [Abstract][Full Text] [Related]
12. Effect of dietary phosphate intake on the circadian rhythm of serum phosphate concentrations in chronic kidney disease: a crossover study.
Ix JH; Anderson CA; Smits G; Persky MS; Block GA
Am J Clin Nutr; 2014 Nov; 100(5):1392-7. PubMed ID: 25332338
[TBL] [Abstract][Full Text] [Related]
13. The effect of feeding a renal diet on plasma fibroblast growth factor 23 concentrations in cats with stable azotemic chronic kidney disease.
Geddes RF; Elliott J; Syme HM
J Vet Intern Med; 2013; 27(6):1354-61. PubMed ID: 24010686
[TBL] [Abstract][Full Text] [Related]
14. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
Molony DA; Stephens BW
Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
[TBL] [Abstract][Full Text] [Related]
15. A prospective study of fibroblast growth factor-23 in children with chronic kidney disease.
Magnusson P; Hansson S; Swolin-Eide D
Scand J Clin Lab Invest; 2010 Feb; 70(1):15-20. PubMed ID: 19929273
[TBL] [Abstract][Full Text] [Related]
16. Acute effects of very-low-protein diet on FGF23 levels: a randomized study.
Di Iorio B; Di Micco L; Torraca S; Sirico ML; Russo L; Pota A; Mirenghi F; Russo D
Clin J Am Soc Nephrol; 2012 Apr; 7(4):581-7. PubMed ID: 22362063
[TBL] [Abstract][Full Text] [Related]
17. Daily variability in mineral metabolites in CKD and effects of dietary calcium and calcitriol.
Isakova T; Xie H; Barchi-Chung A; Smith K; Sowden N; Epstein M; Collerone G; Keating L; Jüppner H; Wolf M
Clin J Am Soc Nephrol; 2012 May; 7(5):820-8. PubMed ID: 22383746
[TBL] [Abstract][Full Text] [Related]
18. Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease.
Manghat P; Fraser WD; Wierzbicki AS; Fogelman I; Goldsmith DJ; Hampson G
Osteoporos Int; 2010 Nov; 21(11):1853-61. PubMed ID: 20012018
[TBL] [Abstract][Full Text] [Related]
19. Use of phosphate binders in chronic kidney disease.
Ketteler M; Biggar PH
Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):413-20. PubMed ID: 23736841
[TBL] [Abstract][Full Text] [Related]
20. Serum klotho: relation to fibroblast growth factor-23 and other regulators of phosphate metabolism in children with chronic kidney disease.
Sawires HK; Essam RM; Morgan MF; Mahmoud RA
Nephron; 2015; 129(4):293-9. PubMed ID: 25766835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
